Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft

Cancer Research

Volumn 57, Issue 14, 1997, Pages 2933-2936

  Friedman, Henry S ^a   Johnson, Stewart P ^a   Dong, Qing ^a   Schold, S Clifford ^e   Rasheed, B K Ahmed ^a   Bigner, Sandra H ^a   Ali Osman, Francis ^b   Dolan, Eileen ^c   Colvin, O Michael ^a   Houghton, Peter ^d   Germain, Glen ^d   Drummond, James T ^a   Keir, Stephen ^a   Marcelli, Susan ^a   Bigner, Darell D ^a   Modrich, Paul ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 O ALKYLGUANINE DNA ALKYLTRANSFERASE; 9 AMINOCAMPTOTHECIN; BUSULFAN; CARMUSTINE; CELL PROTEIN; CYCLOPHOSPHAMIDE; GLUTATHIONE; GLUTATHIONE TRANSFERASE; IRINOTECAN; METHYLNITROSOUREA; PROCARBAZINE; TEMOZOLOMIDE;

ANIMAL CELL; ARTICLE; BASE MISPAIRING; CANCER RESISTANCE; CONTROLLED STUDY; DNA REPAIR; DRUG RESPONSE; DRUG SENSITIVITY; ENZYME ACTIVITY; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; DNA METHYLATION; DNA REPAIR; DRUG RESISTANCE; GLIOBLASTOMA; HUMANS; MELANOCYTE-STIMULATING HORMONES; METHYLTRANSFERASES; MICE; MICE, INBRED BALB C; MICROSATELLITE REPEATS; NEOPLASM TRANSPLANTATION; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0030834332     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Kumar, A. R. V., Renaudin, J., Wilson, C. B., Boldrey, E. B., Enot, K. J., and Levin, V. A. Procarbazine hydrochloride in the treatment of brain tumors. J. Neurosurg., 40: 365-371, 1974.
2. European Organization for Research on Treatment of Cancer (EORTC) Brain Tumor Group. Evaluation of CCNU, VM-26 plus CCNU, and procarbazine in supratentorial brain gliomas. J. Neurosurg., 55: 27-31, 1981.
3. Green, S. B., Byar, D. P., Walker, M. D., Pistenmaa, D. A., Alexander, E., Jr., Batzdorf, U., Brooks, W. H. Hunt, W. E., Mealey, J., Jr., Odom, G. L., Paoletti, P., Ransohoff, J., II, Robertson, J. T., Selker, R. G., Shapiro, W. R., Smith, K. R., Jr., Wilson, C. B., and Strike, T. A. Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat. Rep., 67: 121-132, 1983.
4. Rodriguez, L. A., Prados, M., Silver, P., and Levin, V. A. Reevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumors. Cancer (Phila.), 64: 2420-2423, 1989.
5. Newton, H. B., Junck, L., Bromberg, J., Page, M. A., and Greenberg, H. S. Procarbazine chemotherapy in the treatment of recurrent malignant astrocytomas after radiation and nitrosourea failure. Neurology, 40: 1743-1746, 1993.
6. 6-Alkylguanine-DNA alkyltransferase and sensitivity to procarbazine in human brain-tumor xenografts. J. Neurosurg., 70: 573-577, 1989.
7. Bullard, D. E., Schold, S. C., Jr., Bigner, S. H., and Bigner, D. D. Growth and chemotherapeutic response in athymic mice of tumor arising from human glioma-derived cell line. J. Neuropathol. Exp. Neurol., 40: 410-427, 1981.
8. Friedman, H. S., Colvin, O. M. Skapek, S. X., Ludeman, S. M., Elion, G. B., Schold, S. C., Jr., Jacobsen, P. F., Muhlhaier, L. H., and Bigner, D. D. Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents. Cancer Res., 48: 4189-4195, 1988.
9. Friedman, H. S., Schold, S. C., Jr., Varia, M., and Bigner, D. D. Chemotherapy and radiation therapy of human medulloblastoma in athymic nude mice. Cancer Res., 43: 3008-3093, 1983.
10. 6-alkylguanine pretreatment on the sensitivity of human colon tumor cells to the cytotoxic effects of chloroethylating agents. Cancer Res., 46: 4500-4504, 1986.
11. 6-methylguanine. Cancer Chemother. Pharmacol., 25: 103-108, 1989.
12. Tietze, F. Enzyme method for quantitative determination of nanogram amounts of total and oxidized glutathione. Anal. Biochem., 27: 502-522, 1969.
13. Griffith, O. W. Determination of glutathione and glutathione-disulfide using glutathione reductase and 2-vinylpyridine. Anal. Biochem., 106: 207-212, 1980.
14. Skapek, S. X., Colvin, O. M., Griffith, O. W., Groothuis, D. R., Colapinto, E. V., Lee, Y. S., Hilton, J., Elion, G. B., Bigner, D. D., and Friedman, H. S. Buthionine sulfoximine-mediated depletion of glutathione in intracranial human glioma-derived xenografts. Biochem. Pharmacol., 37: 4313-4317, 1988.
15. Skapek, S., Colvin, O. M., Griffith, O., Elion, G. B., Bigner, D. D., and Friedman, H. S. Enhanced cytotoxicity of melphalan secondary to BSO-mediated depletion of glutathione in medulloblastoma xenografts in athymic nude mice. Cancer Res., 48: 2764-2767, 1988.
16. Habig, W. H., Pabst, M. J., and Jakoby, W. B. Glutathione-S-transferase. The first enzymatic step in mercapturic acid formation. J. Biol. Chem., 249: 7130-7139, 1974.
17. Friedman, H. S., Skapek, S. X., Colvin, O. M., Elion, G. B., Blum, M. R., Savina, P. M., Hilton, J., Schold, S. C., Jr., Kurtzberg, J., and Bigner, D. D. Melphalan transport, glutathione levels, and glutathione-S-transferase activity in human medulloblastoma. Cancer Res., 48: 5397-5402, 1988.
18. Holmes, J., Jr., Clark, S., and Modrich, P. Strand-specific mismatch correction in nuclear extracts of human and Drosophila melanogaster cell lines. Proc. Natl. Acad. Sci. USA, 87: 5837-5841, 1990.
19. Chomczynski, P., and Sacchi, N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem., 162: 156-159, 1987.
20. Liu, B., Parsons, R. E., Hamilton, S. R., Peterson, G. M., Lynch, H. T., Watson, P., Markowitz, S., Wilson, J. K. V., Green, J., de la Chapelle, A., Kinzler, K. W., and Vogelstein, B. HMSH2 mutations in hereditary nonpolyposis colorectal cancer kindreds. Cancer Res., 54: 4590-4594, 1994.
21. Butler, W. B. Preparing nuclei from cells in monolayer culture suitable for counting and for following synchronized cells through the cell cycle. Anal. Biochem., 141: 70-73, 1984.
22. Edwards, M. S., Levin, V. A., and Wilson, C. B. Brain tumor chemotherapy: an evaluation of agents in current use of phase II and III trials. Cancer Treat. Rep., 64: 1179-1205, 1980.
23. Karran, P., and Bignami, M. Self-destruction and tolerance in resistance of mammalian cells to alkylation damage. Nucleic Acids Res., 20: 2933-2940, 1992.
24. Branch, P., Aquilina, G., Bignami, M., and Karran, P. Defective mismatch binding and a mutator phenotype in cells tolerant to DNA damage. Nature (Lond.), 362: 652-654, 1993.
25. Kat, A., Thilly, W. G., Fang, W. H., Longley, M. J., Li, G. M., and Modrich, P. An alkylation-tolerant, mutator human cell line is deficient in strand-specific mismatch repair. Proc. Natl. Acad. Sci. USA, 90: 6424-6428, 1993.
26. Koi, M., Umar, A., Chauhan, D. P., Cherian, S. P., Carethers, J. M., Kunkel, T. A., and Boland, C. R. Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N′-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation (Published erratum appears in Cancer Res., 55: 201, 1995). Cancer Res., 54: 4308-4312, 1994.
27. Aebi, S., Kurdi-Haidar, B., Gordon, P., Cenni, B., Zheng, H., Fink, D., Christen, R. D., Boland, C. R., Koi, M., Fishel, R., and Howell, S. B. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res., 56: 3087-3090, 1996.
28. Drummond, J. T., Anthoney, A., Brown, R., and Modrich, P. Cisplatin and adriamycin resistance are associated with MutLα and mismatch repair deficiency in an ovarian tumor cell line. J. Biol. Chem., 271: 19645-19648, 1996.
29. 4-melhylthymine or the cisplatin-d(GpG) adduct. Proc. Natl. Acad. Sci. USA, 91: 6443-6447, 1996.